Navigation Links
HUYA Bioscience Establishes First-Look Agreement With Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH)

SAN DIEGO, Sept. 15 /PRNewswire/ -- HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products. The agreement with GIBH provides HUYA the exclusive right of first review and negotiation for the licensing and development of certain novel compounds owned or controlled by GIBH.

Over the past four years, HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to speed the development and value creation in worldwide markets for China-sourced product candidates. HUYA has entered into strategic partnerships with many institutions, including Shenyang Pharmaceutical University and the Beijing Institute of Material Medica.

"HUYA continues to be on the forefront of creating partnerships with leading Chinese institutions such as GIBH that will lead to the accelerated development of novel therapeutics," said Dr. Mireille Gingras, HUYA's CEO. "GIBH is an important pharmaceutical R&D institute in South China, and we are excited to partner with this regional leader to identify and pursue novel product opportunities."

GIBH is an innovative and competitive R&D organization with diversified capabilities that include molecular ecology, stem cell biology, cancer cell biology, pharmacological and pathological genomics, structural biology, epidemiology, biotherapeutics, chemical drug, natural drug, preclinical medicine, drug metabolism and pharmacokinetics, vaccine and antibody research, as well as development of equipment for testing and analysis.

HUYA's innovative co-development model

HUYA was one of the first companies to recognize China's potential to help meet the global need for pre-clinical and clinical stage compounds for the drug development process. Leveraging the HUYA Integrated Co-Development Model for partnering with Chinese research institutions and pharmaceutical companies, HUYA identifies and licenses the most promising pre-clinical and clinical stage compounds in China. Through collaborations with its Chinese partners, the company provides a bridge to the global development process and biopharma market.


HUYA is the leader in global pharmaceutical co-development with China. With four strategic offices in China, the broadest Chinese compound portfolio, and more exclusive agreements with premier Chinese biotech centers than any other company, HUYA has pioneered the most innovative and productive approach to pharmaceutical co-development between the U.S. and China. HUYA has joint headquarter offices in San Diego, CA, and Shanghai. Additional information about the company is available at


Guangzhou Institute of Biomedicine and Health (GIBH), as a branch of the Chinese Academy of Sciences, is a government-sponsored institution in China. It was established by the joint efforts of the Chinese Academy of Sciences, Guangdong Provincial Government and Guangzhou Municipal Government, in accordance with the strategic demands for national socio-economic development and international trends in medicine and biopharmaceutical research. GIBH's focus is to become an internationally innovative and competitive R&D organization in the fields of biomedicine, vaccine development and diagnosis, fulfilling the responsibility of tackling key problems with innovation and integration of cutting-edge technologies as well as providing platforms for biomedical science.

    Bob Giargiari, MBA
    EVP Finance & CFO
    HUYA Bioscience International, LLC
    (858) 798-8800

    Qing (Vicky) Xia
    Scientific Research Manager
    HUYA Bioscience International, LLC
    86 (21) 51323312

    Media Contact:
    Juliet Travis
    (510) 452-3771

SOURCE HUYA Bioscience International
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Seahorse Bioscience to Present Novel Cellular Bioenergetics Data in Collaboration with University of Nebraska at AACR Metabolism and Cancer Conference
2. Cell Biosciences Signs Agreement to Acquire Alpha Innotech
3. eBioscience Corporation Acquires NatuTec GmbH
4. Regado Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2009 on September 11, 2009
5. Regado Biosciences to Present at the Rodman & Renshaw Global Investment Conference on September 10, 2009
6. Cardio3 BioSciences Presents Update on C-Cure(R) Second Generation Stem Cell Therapy for Heart Failure at European Society of Cardiology Congress
7. SABiosciences Ranked 17th on the Best Places to Work Industry Award for Biotech and Pharmaceutical Companies
8. California Life Science, Business, and Economic Development Experts Discuss Californias Bioscience Future
9. California Bioscience Business Roundtable Aug. 26th
10. Regado Biosciences Announces First Patient Enrolled In Phase 1 Study Of Subcutaneously Administered Reg1 Anticoagulation System
11. Biosciences Firm Chooses CloudCraze for eCommerce Business Solution -- LI-COR and EDL Consulting Take Expertise into the "Cloud"
Post Your Comments:
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... The ... newest Special Interest Group (SIG), MultiGP, also known as Multirotor Grand Prix, to represent ... the last few years. Many AMA members have embraced this type of racing and ...
(Date:11/24/2015)... 24, 2015 --> ... report released by Transparency Market Research, the global non-invasive ... CAGR of 17.5% during the period between 2014 and ... Global Industry Analysis, Size, Volume, Share, Growth, Trends and ... testing market to reach a valuation of US$2.38 bn ...
(Date:11/24/2015)... /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) (TSX: ... 11,000 post-share consolidation (or 1,100,000 pre-share consolidation) Series ... Warrants") subject to the previously disclosed November 1, ... which will result in the issuance of 365,518 ... issuance of such shares, there will be approximately ...
Breaking Biology Technology:
(Date:10/26/2015)...  Delta ID Inc., a company focused on bringing ... devices, announced its ActiveIRIS® technology powers the iris recognition ... by NTT DOCOMO, INC in Japan ... to include iris recognition technology, after a very successful ... May 2015, world,s first smartphone to have this capability. ...
(Date:10/23/2015)... and GOLETA, California , ... HFES conference, BIOPAC and SensoMotoric Instruments (SMI) announce a ... eye tracking data captured during interactive real-world tasks ... and play integration of their established wearable solutions for ... to synchronize gaze behavior captured with SMI Eye ...
(Date:10/22/2015)... SAN JOSE, Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ... results for its first quarter ended September 30, 2015. ... first quarter of fiscal 2016 grew 66 percent over the comparable ... quarter of fiscal 2016 was $23.8 million, or $0.62 per diluted ... net income for the first quarter of fiscal 2016 grew 39 ...
Breaking Biology News(10 mins):